Search

Objectives: COVID-19, caused by SARS-CoV-2, has spread around the world since 2019. In severe cases, COVID-19 can lead to hospitalization and death. Systemic arterial hypertension and other comorbidities are associated with serious COVID-19 infection. Literature is unclear whether antihypertensive therapy with angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors affect COVID-19 outcomes. We aim to assess whether ACEI/ARB therapy is a risk factor for worse respiratory outcomes related to COVID-19 in hospitalized patients., Methods: Retrospective study enrolling admitted COVID-19-diagnosed patients by RT-PCR at the Hospital Geral de Fortaleza, Brazil, during 2021. Patient medical records, sociodemographic, and clinical data were analyzed. Chest CT images were analyzed using CAD4COVID-CT/Thirona™ software., Results: A total of 294 patients took part in the study. A cut-off point of 66% of pulmonary involvement was found by ROC curve, with patients having higher risk of death and intubation and lower 60-day survival. Advanced age (RR 1.025, P=0.001) and intubation (RR 16.747, P<0.001) were significantly associated with a higher risk of death. Advanced age (RR 1.023, P=0.001) and the use of noninvasive ventilation (RR 1.548, P=0.037) were associated with a higher risk of intubation. Lung involvement (>66%) increased the risk of death by almost 2.5-fold (RR 2.439, P<0.001) and by more than 2.3-fold the risk of intubation (RR 2.317, P<0.001)., Conclusions: Altogether, our findings suggest that ACEI or ARB therapy does not affect the risk of death and disease course during hospitalization., (Copyright © 2023 Elsevier España, S.L.U. All rights reserved.)

Copyright of Revista de Ciencias Médicas de Pinar del Río is the property of Editorial Ciencias Medicas and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Even though currently the cornerstone of research and treatment of COVID-19 patients has been the respiratory system, it is essential to consider that COVID-19 has multiple extrapulmonary manifestations, some severe enough to be fatal. For this reason this review focuses on three intimately related systems: cadiovascular, renal and hematological systems. SARS-CoV-2 enters cells through angiotensin converting enzyme 2 (ACE2), a key regulator of the renin-angiotensinaldosterone system (RAAS), which has been characterized in multiple cardiovascular and renal diseases. The hyperinflammatory state in COVID-19 leads to microvascular dysfunction, hypercoagulability, arrhythmias, and acute kidney injury. The importance of diverse multisystemic markers should be highlighted, they have been shown to be predictors of severity and highly useful in the management of patients with COVID-19 to avoid future complications related to the disease. [ABSTRACT FROM AUTHOR]

Introduction: COVID-19 caused by the SARS-CoV-2 virus is a pandemic that has claimed the lives of millions of people and overloaded health services around the world. Objective: to describe the relationship between the spike protein (S) of SARS-CoV-2 and the angiotensin-converting enzyme 2 as the primary trigger of COVID-19 infection. Method: a bibliographic search was carried out in Google Scholar, SciELO and PubMed, with the initial descriptors COVID-19 and SARS-CoV-2. The publication period selected was between the years 2019 to 2021, without restrictions regarding the type of article. The papers had to be available in full text in Spanish and English. Results: the spike protein of SARS-CoV-2, which plays a key role in receptor recognition and in the cell membrane fusion process, is composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) that binds to the host's receptor, angiotensin-converting enzyme 2, while the S2 subunit is involved in the viral and cellular membrane fusion. The tissue ubiquity of angiotensin converting enzyme 2 explains the multiple clinical manifestations of the disease. Conclusions: the knowledge of the relationship between SARS-CoV-2 and its receptor the angiotensin-converting enzyme 2, allows not only to know the pathophysiology of COVID-19, but also the design of antiviral drugs and vaccines that contribute to the prevention and treatment of this viral disease.

Copyright of Revista ADM is the property of Asociacion Dental Mexicana and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

El síndrome respiratorio agudo severo (SRAS), es causado por el coronavirus (SARS-CoV-2); este utiliza el receptor de la enzima convertidora de angiotensina 2 (ACE2), para invadir los cuerpos humanos. En diciembre de 2019 surgió un brote sin precedentes de neumonía de etiología desconocida en la ciudad de Wuhan, provincia de Hubei en China. El brote se informó a la OMS el 31 de diciembre de 2019, quien el 11 de febrero lo denominó COVID-19. América Latina no fue la excepción a este problema de salud pública: el 25 de febrero de 2020, el Ministerio de Salud de Brasil confirmó el primer caso confirmado un hombre brasileño, de 61 años. Actualmente, pese a los rigurosos esfuerzos globales de contención y cuarentena, la incidencia de COVID-19 continúa aumentando, con 3 435 894 casos confirmados por laboratorio y más de 239 000 muertes en todo el mundo. En respuesta a este brote global, realizaremos una revisión, de la epidemiología a nivel de América Latina.

From the begining of the coronavirus (sAr-cov-2) pandemia in december 2019, the world cientific information has been very dynamic in the clinical presentation, fisiopathology and the treatment of this infection. there are few prospective published studies and many in process. two receptores the angiotensin converting enzyme 2 (Ace2) and the transmembrane serine protease 2 (tMPrss2).has been determined for the viral entrance and fusion to the gastrointestinal epithelial cells. the gastric ph inhibitory viral role has been enphasized. the alteration of the microbiota (disbiosis) has emerged due to its important effect on the clinical susceptibility and severity progression of the covId-19 patient, related with the intestine-lung axis, which is the cross talk and exchange of inflammatory mediator between the intestine and the lung, through blood and lymphatic circulation, migrate to the intestine and bind to the Ace2 receptores highly expressed in the enterocyts. the most frequent digestive manifestations are anorexia and taste alterations, diarrhea, nausea, vomiting, hiccup and abdominal pain. nowaday, new therapeutic strategies are mainly foccused on the immune system stimulation with prebiotics, probiotics and some micronutrients, including vitamins c, d, e, zinc and omega 3, among others. It concludes, thar the digestive system is the second organ most affected after the respiratory system and the gstrointestinal manifestations are more common in the pediatric age, with more viral fecal excretion, which sholud be kept in mind for preventive reccomentations. [ABSTRACT FROM AUTHOR]

Copyright of Síndrome Cardiometabólico is the property of Sindrome Cardiometabolico and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Síndrome Cardiometabólico is the property of Sindrome Cardiometabolico and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)